

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,274
				Filing Date	March 23, 2006
				First Named Inventor	Yanagisawa et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	251371
Sheet	1	of	1	Client Reference No.	201257

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
OK	AA	JP	10-310524	A	SANKYO CO. LTD.	Nov. 24, 1998		X*
OK	AB	JP	2002-255813	A	FUSO PHARMACEUTICAL INDUSTRIES, LTD.	Sep. 11, 2002		X*
OK	AC	WO	02/083127	A1	Miyata	Oct. 24, 2002		X*

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
OK	AD	DANNLEY et al., <i>Canadian Journal of Chemistry</i> , 43: 2610-2612 (1965)			
OK	AE	KIM et al., <i>Korean Journal of Medicinal Chemistry</i> , 5(1): 28-37 (1995)			
OK	AF	LEWIS et al., <i>The New England Journal of Medicine</i> , 329(20): 1456-1462 (Nov. 11, 1993)			
OK	AG	UENO, <i>Japanese Journal of Clinical Medicine (Nippon Rinsho)</i> , 60(10): 1999-2004 (Oct. 1, 2002)		X*	
OK	AH	YAMAMOTO et al., <i>Chem. Pharm. Bull.</i> , 46(11): 1716-1723 (Nov. 1998)			

Examiner Signature		Date Considered	10/19/07
--------------------	--	-----------------	----------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).